BACKGROUND AND OBJECTIVE: Icodec is a once-weekly insulin being developed to provide basal insulin coverage in diabetes mellitus. This study evaluated the effects of renal or hepatic impairment on icodec pharmacokinetics. METHODS: Two open-label, parallel-group, single-dose (1.5 U/kg subcutaneously) trials were conducted. In a renal impairment trial, 58 individuals were allocated to normal renal function (measured glomerular filtration rate ≥ 90 mL/min), mild (60 to < 90 mL/min), moderate (30 to < 60 mL/min) or severe (< 30 mL/min) renal impairment or end-stage renal disease. In a hepatic impairment trial, 25 individuals were allocated to normal hepatic function or mild (Child-Pugh Classification grade A), moderate (grade B) or severe (grade C) hepatic impairment. Blood was sampled frequently for a pharmacokinetic analysis until 35 days post-dose. RESULTS: The shape of the icodec pharmacokinetic profile was not affected by renal or hepatic impairment. Total icodec exposure was greater for mild (estimated ratio [95% confidence interval]: 1.12 [1.01; 1.24]), moderate (1.24 [1.12; 1.37]) and severe (1.28 [1.16; 1.42]) renal impairment, and for end-stage renal disease (1.14 [1.03; 1.28]), compared with normal renal function. It was also greater for mild (1.13 [1.00; 1.28]) and moderate (1.15 [1.02; 1.29]) hepatic impairment versus normal hepatic function. There was no statistically significant difference between severe hepatic impairment and normal hepatic function. Serum albumin levels (range 2.7-5.1 g/dL) did not statistically significantly influence icodec exposure. CONCLUSIONS: The clinical relevance of the slightly higher icodec exposure with renal or hepatic impairment is limited as icodec should be dosed according to individual need. No specific icodec dose adjustment is required in renal or hepatic impairment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03723785 and NCT04597697.

Charité Research Organisation Berlin Germany

Dérer's Hospital Comenius University Bratislava Slovakia

ICON Prague Czech Republic

Novo Nordisk Aalborg Denmark

Novo Nordisk Shanghai China

Novo Nordisk Søborg Denmark

See more in PubMed

Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–2045. doi: 10.2215/CJN.11491116. PubMed DOI PMC

Fried LF, Folkerts K, Smeta B, et al. Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021;27(Suppl. 8):S168–S177. doi: 10.37765/ajmc.2021.88660. PubMed DOI

Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13:1085–1095. doi: 10.2215/CJN.00340118. PubMed DOI PMC

Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol. 2018;13:1254–1263. doi: 10.2215/CJN.05150418. PubMed DOI PMC

Pina AF, Borges DO, Meneses MJ, et al. Insulin: trigger and target of renal functions. Front Cell Dev Biol. 2020;8:519. doi: 10.3389/fcell.2020.00519. PubMed DOI PMC

Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018;217:2273–2289. doi: 10.1083/jcb.201802095. PubMed DOI PMC

Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–890. doi: 10.2337/diacare.24.5.886. PubMed DOI

Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827–835. doi: 10.2147/IJGM.S26889. PubMed DOI PMC

Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469–476. doi: 10.1111/j.1365-2125.2005.02476.x. PubMed DOI PMC

Jacobsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45(Suppl 2):A259. doi: 10.1007/BF03375460. DOI

Kiss I, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53:175–183. doi: 10.1007/s40262-013-0113-2. PubMed DOI PMC

Talal AH, Venuto CS, Younis I. Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clin Pharmacol Drug Dev. 2017;6:206–212. doi: 10.1002/cpdd.336. PubMed DOI PMC

Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734–743. doi: 10.2337/dc06-1539. PubMed DOI

Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64:8942–8950. doi: 10.1021/acs.jmedchem.1c00257. PubMed DOI

Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414–425. doi: 10.1016/S2213-8587(23)00093-1. PubMed DOI

Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330:228–237. doi: 10.1001/jama.2023.11313. PubMed DOI PMC

Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389:297–308. doi: 10.1056/NEJMoa2303208. PubMed DOI

Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929–1940. doi: 10.1016/S0140-6736(23)00520-2. PubMed DOI

Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9:e002301. doi: 10.1136/bmjdrc-2021-002301. PubMed DOI PMC

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150. doi: 10.1038/kisup.2012.73. DOI

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649. doi: 10.1002/bjs.1800600817. PubMed DOI

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006. PubMed DOI PMC

Plum-Mörschel L, Andersen LR, Hansen S, et al. Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Investig. 2023;43:119–127. doi: 10.1007/s40261-022-01243-6. PubMed DOI PMC

ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic targets: standards of care in diabetes: 2023. Diabetes Care. 2023;46(Suppl 1):S97–110. doi: 10.2337/dc23-S006. PubMed DOI PMC

Kupčová V, Arold G, Roepstorff C, et al. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014;34:127–133. doi: 10.1007/s40261-013-0154-1. PubMed DOI PMC

Najjar SM, Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology. 2019;34:198–215. doi: 10.1152/physiol.00048.2018. PubMed DOI PMC

Meijer RI, Barrett EJ. The insulin receptor mediates insulin's early plasma clearance by liver, muscle, and kidney. Biomedicines. 2021;9:37. doi: 10.3390/biomedicines9010037. PubMed DOI PMC

Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383:2107–2116. doi: 10.1056/NEJMoa2022474. PubMed DOI

Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44:1586–1594. doi: 10.2337/dc20-2877. PubMed DOI PMC

Lingvay I, Buse JB, Franek E, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. 2021;44:1595–1603. doi: 10.2337/dc20-2878. PubMed DOI PMC

Fujiwara S, Amisaki T. Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Biophys J. 2008;94:95–103. doi: 10.1529/biophysj.107.111377. PubMed DOI PMC

van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009;24:300–307. doi: 10.2133/dmpk.24.300. PubMed DOI

European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed 15 Jan 2024.

European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Accessed 15 Jan 2024.

See more in PubMed

ClinicalTrials.gov
NCT03723785, NCT04597697